Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer.
Bhalla S, Fattah FJ, Ahn C, Williams J, Macchiaroli A, Padro J, Pogue M, Dowell JE, Putnam WC, McCracken N, Micklem D, Brekken RA, Gerber DE. Bhalla S, et al. Among authors: brekken ra. Lung Cancer. 2023 Aug;182:107291. doi: 10.1016/j.lungcan.2023.107291. Epub 2023 Jul 4. Lung Cancer. 2023. PMID: 37423058 Free PMC article. Clinical Trial.
Stromal platelet-derived growth factor receptor α (PDGFRα) provides a therapeutic target independent of tumor cell PDGFRα expression in lung cancer xenografts.
Gerber DE, Gupta P, Dellinger MT, Toombs JE, Peyton M, Duignan I, Malaby J, Bailey T, Burns C, Brekken RA, Loizos N. Gerber DE, et al. Among authors: brekken ra. Mol Cancer Ther. 2012 Nov;11(11):2473-82. doi: 10.1158/1535-7163.MCT-12-0431. Epub 2012 Aug 28. Mol Cancer Ther. 2012. PMID: 22933705 Free PMC article.
Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts.
Gerber DE, Hao G, Watkins L, Stafford JH, Anderson J, Holbein B, Öz OK, Mathews D, Thorpe PE, Hassan G, Kumar A, Brekken RA, Sun X. Gerber DE, et al. Among authors: brekken ra. Am J Nucl Med Mol Imaging. 2015 Oct 12;5(5):493-503. eCollection 2015. Am J Nucl Med Mol Imaging. 2015. PMID: 26550540 Free PMC article.
Axl Receptor Axis: A New Therapeutic Target in Lung Cancer.
Levin PA, Brekken RA, Byers LA, Heymach JV, Gerber DE. Levin PA, et al. Among authors: brekken ra. J Thorac Oncol. 2016 Aug;11(8):1357-1362. doi: 10.1016/j.jtho.2016.04.015. Epub 2016 Apr 26. J Thorac Oncol. 2016. PMID: 27130831 Free PMC article.
AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells.
Lotsberg ML, Wnuk-Lipinska K, Terry S, Tan TZ, Lu N, Trachsel-Moncho L, Røsland GV, Siraji MI, Hellesøy M, Rayford A, Jacobsen K, Ditzel HJ, Vintermyr OK, Bivona TG, Minna J, Brekken RA, Baguley B, Micklem D, Akslen LA, Gausdal G, Simonsen A, Thiery JP, Chouaib S, Lorens JB, Engelsen AST. Lotsberg ML, et al. Among authors: brekken ra. J Thorac Oncol. 2020 Jun;15(6):973-999. doi: 10.1016/j.jtho.2020.01.015. Epub 2020 Feb 1. J Thorac Oncol. 2020. PMID: 32018052 Free PMC article.
230 results